{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:55:22Z","timestamp":1794934522442,"version":"4.9.1"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The aim of this review is to provide an account of the focus of therapeutic strategies for hereditary angioedema (HAE), give a brief overview of those used in the past and set aside and toughly discuss those currently available as first line. Further research is ongoing and the future therapeutic approaches that are still in different phases of study will be reviewed as well.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In the last two decades, major research advancements on HAE pathophysiology and management were made and numerous novel therapeutic options are now available. Compared to the past, drugs available nowadays are more effective, well tolerated, and possibly have a more convenient administration route. Moreover, numerous other drugs with innovative mechanisms of action are under development.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>HAE is a rare genetic disease that if not promptly treated, it can lead to death from asphyxiation. Furthermore, due to its disfiguring and painful manifestations, HAE implies an important burden on the quality of life. Recently, following great research progresses on HAE therapy, evidence-based guidelines on HAE management were released. The therapeutic landscape of HAE is still under florid development, and it is possible novel treatments will remarkably revolutionize HAE management in the future.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aci.0000000000000992","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T16:02:39Z","timestamp":1715702559000},"page":"257-265","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Hereditary angioedema: current therapeutic management and future approaches"],"prefix":"10.1097","volume":"24","author":[{"given":"Donatella","family":"Lamacchia","sequence":"first","affiliation":[{"name":"Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Nappi","sequence":"additional","affiliation":[{"name":"Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Marzio","sequence":"additional","affiliation":[{"name":"Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital"},{"name":"Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Locatelli","sequence":"additional","affiliation":[{"name":"Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Messina","sequence":"additional","affiliation":[{"name":"Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital"},{"name":"Department of Biomedical Sciences, Humanitas University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Heffler","sequence":"additional","affiliation":[{"name":"Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital"},{"name":"Department of Biomedical Sciences, Humanitas University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM199606203342510","article-title":"Hereditary angioedema","volume":"334","author":"Cicardi","year":"1996","journal-title":"N Engl J Med"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2249.2005.02726.x","article-title":"C1 inhibitor deficiency: consensus document","volume":"139","author":"Gompels","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12016-021-08897-8","article-title":"The mortality from hereditary angioedema worldwide: a review of the real-world data literature","volume":"62","author":"Minafra","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"100758","DOI":"10.1016\/j.waojou.2023.100758","article-title":"A narrative review of recent literature of the quality of life in hereditary angioedema patients","volume":"16","author":"Chong-Neto","year":"2023","journal-title":"World Allergy Organ J"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1067\/mai.2000.110471","article-title":"Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema","volume":"106","author":"Pappalardo","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"540","DOI":"10.2340\/00015555-2274","article-title":"Hereditary angioedema in Swedish adults: report from the national cohort","volume":"96","author":"Nordenfelt","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"R7-20250527","first-page":"416","article-title":"Hereditary angioedema in Austria: prevalence and regional peculiarities","volume":"17","author":"Sch\u00f6ffl","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00005792-199207000-00003","article-title":"Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients","volume":"71","author":"Agostoni","year":"1992","journal-title":"Medicine"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","article-title":"Hereditary angioedema: new findings concerning symptoms, affected organs, and course","volume":"119","author":"Bork","year":"2006","journal-title":"Am J Med"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.therap.2020.02.011","article-title":"Update on bradykinin-mediated angioedema in 2020","volume":"75","author":"Lepelley","year":"2020","journal-title":"Therapies"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1172\/JCI113252","article-title":"Restriction fragment length polymorphism of the C1 inhibitor gene in hereditary angioneurotic edema","volume":"80","author":"Cicardi","year":"1987","journal-title":"J Clin Invest"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198707023170101","article-title":"Altered C1 inhibitor genes in type I hereditary angioedema","volume":"317","author":"Stoppa-Lyonnet","year":"1987","journal-title":"N Engl J Med"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.148.3672.957","article-title":"Hereditary angioneurotic edema: two genetic variants","volume":"148","author":"Rosen","year":"1965","journal-title":"Science"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/humu.23917","article-title":"SERPING1 mutation update: mutation spectrum and C1 Inhibitor phenotypes","volume":"41","author":"Ponard","year":"2020","journal-title":"Hum Mutat"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaip.2018.04.022","article-title":"Angioedema due to bradykinin dysregulation","volume":"6","author":"Cicardi","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 Guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"238","DOI":"10.18176\/jiaci.0875","article-title":"Expert review and consensus on the treat-to-target management of hereditary angioedema: from scientific evidence to clinical practice","volume":"33","author":"Caballero","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18176\/jiaci.0653","article-title":"Treatment of hereditary angioedema","volume":"31","author":"Caballero","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"383","DOI":"10.18176\/jiaci.0102","article-title":"Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema","volume":"26","author":"Caballero","year":"2016","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/j.1398-9995.2011.02702.x","article-title":"C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the I.M.P.A.C.T.2 study","volume":"66","author":"Craig","year":"2011","journal-title":"Allergy"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2500\/aap.2011.32.3440","article-title":"Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials","volume":"32","author":"Banta","year":"2011","journal-title":"Allergy Asthma Proc"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"e53773","DOI":"10.1371\/journal.pone.0053773","article-title":"Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment","volume":"8","author":"Maurer","year":"2013","journal-title":"PLoS One"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13023-020-1334-8","article-title":"Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene","volume":"15","author":"Bork","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/all.13076","article-title":"Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII)","volume":"72","author":"Bork","year":"2017","journal-title":"Allergy"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1684\/ejd.2016.2948","article-title":"Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert\u00ae) in a French cohort","volume":"27","author":"Bouillet","year":"2017","journal-title":"Eur J Dermatol"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2217\/imt.15.44","article-title":"Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency","volume":"7","author":"Moldovan","year":"2015","journal-title":"Immunotherapy"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0805538","article-title":"Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema","volume":"363","author":"Zuraw","year":"2010","journal-title":"N Engl J Med"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaci.2010.07.021","article-title":"Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema","volume":"126","author":"Zuraw","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/17512433.2020.1776110","article-title":"Thromboembolic risk of C1 esterase inhibitors: a systematic review on current evidence","volume":"13","author":"Burnham","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40261-013-0064-2","article-title":"Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of ige antibodies","volume":"33","author":"Hack","year":"2013","journal-title":"Clin Drug Investig"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJMoa0906393","article-title":"Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"key":"R33-20250527","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2500\/aap.2014.35.3780","article-title":"Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting","volume":"35","author":"Maurer","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2125.2010.03642.x","article-title":"Icatibant","volume":"69","author":"Dubois","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1517\/14712598.8.8.1187","article-title":"Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery","volume":"8","author":"Lehmann","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"R36-20250527","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.anai.2010.04.012","article-title":"EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema","volume":"104","author":"Levy","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R37-20250527","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa0905079","article-title":"Ecallantide for the treatment of acute attacks in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"key":"R38-20250527","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaci.2011.03.006","article-title":"Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies","volume":"128","author":"Sheffer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R39-20250527","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jaip.2019.01.054","article-title":"Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks","volume":"7","author":"Craig","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R40-20250527","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","article-title":"Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor","volume":"376","author":"Longhurst","year":"2017","journal-title":"N Engl J Med"},{"key":"R41-20250527","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaip.2019.01.021","article-title":"Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study","volume":"7","author":"Lumry","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R42-20250527","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/all.12658","article-title":"Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate","volume":"70","author":"Zuraw","year":"2015","journal-title":"Allergy"},{"key":"R43-20250527","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13223-019-0328-3","article-title":"Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks","volume":"15","author":"Bernstein","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R44-20250527","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"R45-20250527","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/all.15011","article-title":"Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE Study","volume":"77","author":"Banerji","year":"2022","journal-title":"Allergy"},{"key":"R46-20250527","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14680","article-title":"Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study","volume":"76","author":"Lumry","year":"2021","journal-title":"Allergy"},{"key":"R47-20250527","doi-asserted-by":"crossref","first-page":"AB9","DOI":"10.1016\/j.jaci.2023.11.051","article-title":"Real-world treatment outcomes of lanadelumab in the prevention of hereditary angioedema attacks: an interim analysis of a Polish, prospective, multicenter, observational study (CHOPIN)","volume":"153","author":"Kucharczyk","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R48-20250527","doi-asserted-by":"crossref","first-page":"978","DOI":"10.36849\/JDD.2020.5269","article-title":"Prospective analysis in patients with HAE under prophylaxis with Lanadelumab: a real-life experience","volume":"19","author":"Hahn","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"R49-20250527","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1016\/j.jaip.2021.04.072","article-title":"Lanadelumab efficacy, safety, and injection interval extension in HAE: a real-life study","volume":"9","author":"Buttgereit","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R50-20250527","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2217\/imt-2019-0128","article-title":"Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema","volume":"11","author":"Hwang","year":"2019","journal-title":"Immunotherapy"},{"key":"R51-20250527","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1716995","article-title":"Oral plasma Kallikrein inhibitor for prophylaxis in hereditary angioedema","volume":"379","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2018","journal-title":"N Engl J Med"},{"key":"R52-20250527","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","article-title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"148","author":"Zuraw","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R53-20250527","doi-asserted-by":"crossref","first-page":"e12035","DOI":"10.1002\/clt2.12035","article-title":"Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study","volume":"11","author":"Farkas","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"R54-20250527","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaip.2023.12.019","article-title":"Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: the open-label extension of the APeX-2 randomized trial","volume":"12","author":"Kiani-Alikhan","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R55-20250527","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/all.15641","article-title":"Berotralstat for the prophylaxis of hereditary angioedema\u2014real-world evidence data from the United Kingdom","volume":"78","author":"Ahuja","year":"2023","journal-title":"Allergy"},{"key":"R56-20250527","doi-asserted-by":"crossref","first-page":"AB135","DOI":"10.1016\/j.jaci.2022.12.423","article-title":"Real-world outcomes in patients with hereditary angioedema (HAE) treated with berotralstat","volume":"151","author":"Anderson","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R57-20250527","doi-asserted-by":"crossref","first-page":"AB93","DOI":"10.1016\/j.jaci.2023.11.308","article-title":"Real-world effectiveness of berotralstat in HAE with and without C1-inhibitor deficiency","volume":"153","author":"Tracy","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R58-20250527","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12016-023-08972-2","article-title":"A retrospective analysis of long-term prophylaxis with berotralstat in patients with hereditary angioedema and acquired C1-inhibitor deficiency\u2014real-world data","volume":"65","author":"Johnson","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"R59-20250527","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/all.15861","article-title":"Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study","volume":"79","author":"Magerl","year":"2024","journal-title":"Allergy"},{"key":"R60-20250527","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.anai.2022.08.580","article-title":"Matching-adjusted indirect treatment comparison between lanadelumab and berotralstat for hereditary angioedema prophylaxis","volume":"129","author":"Watt","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R61-20250527","doi-asserted-by":"crossref","first-page":"e220188","DOI":"10.57264\/cer-2022-0188","article-title":"Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema","volume":"12","author":"Watt","year":"2023","journal-title":"J Comp Eff Res"},{"key":"R62-20250527","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tripleo.2011.02.034","article-title":"Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study","volume":"112","author":"Bork","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"R63-20250527","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/all.12032","article-title":"Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor \u2013 a long-term survey","volume":"67","author":"Farkas","year":"2012","journal-title":"Allergy"},{"key":"R64-20250527","doi-asserted-by":"crossref","first-page":"AB37","DOI":"10.1016\/j.jaci.2018.12.113","article-title":"Recombinant human C1 esterase inhibitor as short-term prophylaxis for dental procedures in patients with angioedema: a case series","volume":"143","author":"Valerieva","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R65-20250527","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0278-2391(99)90280-X","article-title":"The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures","volume":"57","author":"Farkas","year":"1999","journal-title":"J Oral Maxillofac Surg"},{"key":"R66-20250527","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(22)02406-0","article-title":"An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial","volume":"401","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2023","journal-title":"Lancet"},{"key":"R67-20250527","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.anai.2023.08.122","article-title":"Deucrictibant immediate-release capsule reduces time to end of progression of hereditary angioedema attacks\u2019 manifestations","volume":"131","author":"Riedl","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R68-20250527","doi-asserted-by":"crossref","first-page":"AB134","DOI":"10.1016\/j.jaci.2022.12.419","article-title":"Efficacy and safety of bradykinin B2 receptor inhibition with oral PHVS416 in treating hereditary angioedema attacks: results Of RAPIDe-1 Phase 2 trial","volume":"151","author":"Maurer","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R69-20250527","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"R70-20250527","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.123.001740","article-title":"STAR-0215 is a novel, long-acting monoclonal antibody inhibitor of plasma Kallikrein for the potential treatment of hereditary angioedema","volume":"387","author":"Bedian","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"R71-20250527","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/nat.2018.0753","article-title":"Integrated assessment of the clinical performance of GalNAc3 -conjugated 2\u2032- O -methoxyethyl chimeric antisense oligonucleotides: I. Human volunteer experience","volume":"29","author":"Crooke","year":"2019","journal-title":"Nucleic Acid Ther"},{"key":"R72-20250527","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/nat.2018.0754","article-title":"IONIS-PKK a novel antisense inhibitor of prekallikrein and bradykinin production","volume":"29","author":"Ferrone","year":"2019","journal-title":"Nucleic Acid Ther"},{"key":"R73-20250527","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJMoa1915035","article-title":"Antisense inhibition of prekallikrein to control hereditary angioedema","volume":"383","author":"Cohn","year":"2020","journal-title":"N Engl J Med"},{"key":"R74-20250527","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1056\/NEJMoa2109329","article-title":"Inhibition of prekallikrein for hereditary angioedema","volume":"386","author":"Fijen","year":"2022","journal-title":"N Engl J Med"},{"key":"R75-20250527","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.anai.2023.08.091","article-title":"HAE prophylaxis by targeting prekallikrein with siRNA- phase 1 interim safety outcomes and prekallikrein levels","volume":"131","author":"Smith","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R76-20250527","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1261\/rna.068916.118","article-title":"An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema","volume":"25","author":"Liu","year":"2019","journal-title":"RNA"},{"key":"R77-20250527","doi-asserted-by":"crossref","first-page":"AB169","DOI":"10.1016\/j.jaci.2021.12.560","article-title":"CRISPR\/Cas9-mediated KLKB1 gene editing and serum kallikrein reduction by NTLA-2002 remains durable in humanized mice following liver regeneration after partial hepatectomy","volume":"149","author":"Walsh","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R78-20250527","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"N Engl JMed"}],"container-title":["Current Opinion in Allergy &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000000992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T18:05:11Z","timestamp":1748369111000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0000000000000992","relation":{},"ISSN":["1528-4050","1473-6322"],"issn-type":[{"value":"1528-4050","type":"print"},{"value":"1473-6322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]}}}